Melissa McCaffrey, PA
Physician Assistant · Buffalo, NYNPI 1760018097
Payments from drug & device makers
Across 251 payments — averaging $19.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$782
- AstraZeneca$500
- Boehringer Ingelheim$473
- Novo Nordisk$409
- Pfizer$398
- Phathom Pharmaceuticals, Inc.$267
- plus $2K from 32 others
What the payments were for
- Food & beverage$4,965100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 55 | $782 |
| AstraZeneca | 18 | $500 |
| Boehringer Ingelheim | 21 | $473 |
| Novo Nordisk | 23 | $409 |
| Pfizer | 21 | $398 |
| Phathom Pharmaceuticals, Inc. | 8 | $267 |
| Amgen | 11 | $267 |
| Axsome Therapeutics, Inc. | 7 | $230 |
| Exact Sciences | 8 | $191 |
| Merck | 9 | $162 |
| GSK | 9 | $157 |
| AbbVie | 6 | $123 |
| Astellas Pharma US Inc | 6 | $108 |
| Sumitomo Pharma America, Inc. | 4 | $101 |
| E.r. Squibb & Sons, L.L.C. | 6 | $93 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $87 |
| Amarin Pharma, Inc. | 6 | $81 |
| Edwards Lifesciences | 2 | $54 |
| Bayer | 3 | $53 |
| Nestle Healthcare Nutrition Inc. | 3 | $45 |
| Boston Scientific | 2 | $41 |
| Johnson & Johnson | 2 | $38 |
| Daiichi Sankyo Inc. | 2 | $30 |
| Kyowa Kirin, Inc. | 1 | $30 |
| Insulet Corporation | 1 | $27 |
| Inspire Medical Systems, Inc. | 1 | $24 |
| Abbott | 1 | $22 |
| Lundbeck LLC | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Upsher-smith Laboratories LLC | 1 | $17 |
| Corcept Therapeutics | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| Dexcom, Inc. | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| GRT US Holding, Inc. | 1 | $13 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,965 in reported general payments places this provider in the 90th percentile of 11,358 physician assistant providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 11 | $23,871 |
| JardianceEmpagliflozin | 11 | $17,295 |
| MounjaroTirzepatide | 12 | $11,055 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $5,156 |
| Wixela InhubFluticasone Propion/Salmeterol | 14 | $2,651 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 37 | $1,506 |
| Rosuvastatin Calcium | 56 | $1,327 |
| Atorvastatin Calcium | 73 | $1,251 |
| Fluticasone Propionate | 42 | $980 |
| SynthroidLevothyroxine Sodium | 15 | $935 |
| Levothyroxine Sodium | 45 | $900 |
| Ramelteon | 16 | $754 |
| Ezetimibe | 28 | $728 |
| Metformin Hcl ErMetformin Hcl | 50 | $692 |
| Omeprazole | 42 | $585 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $409 | $23,87111 claims |
| Boehringer IngelheimJardiance | $473 | $17,29511 claims |
| Lilly USA, LLCMounjaro | $782 | $11,05512 claims |
| GSKAnoro Ellipta | $157 | $5,15611 claims |
| AbbVieSynthroid | $123 | $93515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 11,358 physician assistant providers in New York.
Other physician assistant in Buffalo
- Scott SpringerBuffalo$95K
- Henry YuBronx$1M
- Michael AsbachAmherst$962K
- Janelle BunceJamestown$565K
- Kristyl Cuenca-SiskoNew York$478K
- Melissa WhiteGarden City$320K
- Lawrence HermanHolbrook$315K
- Kaitlyn NelsonBrooklyn$289K
- Sari KatzGarden City$271K
- Julius NwosuBronx$256K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.